302 related articles for article (PubMed ID: 29034207)
1. Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer.
Daoud A; Chu QS
Front Oncol; 2017; 7():222. PubMed ID: 29034207
[TBL] [Abstract][Full Text] [Related]
2. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
[TBL] [Abstract][Full Text] [Related]
3. Dual drive coexistence of
Zhu YC; Wan B; Wu LX; Li XL; Wang WX; Xu CW; Zhuang W; Wei JG; Du KQ
Transl Cancer Res; 2019 Aug; 8(4):1630-1634. PubMed ID: 35116907
[TBL] [Abstract][Full Text] [Related]
4. Targeting
Baik CS; Myall NJ; Wakelee HA
Oncologist; 2017 Jul; 22(7):786-796. PubMed ID: 28487464
[TBL] [Abstract][Full Text] [Related]
5. Recent Progress in Rare Oncogenic Drivers and Targeted Therapy For Non-Small Cell Lung Cancer.
Guo Y; Cao R; Zhang X; Huang L; Sun L; Zhao J; Ma J; Han C
Onco Targets Ther; 2019; 12():10343-10360. PubMed ID: 31819518
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.
Saxena P; Singh PK; Malik PS; Singh N
Curr Treat Options Oncol; 2020 Jul; 21(8):69. PubMed ID: 32720019
[TBL] [Abstract][Full Text] [Related]
7. A phase I/II trial of weekly nab-paclitaxel for pretreated non-small-cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement.
Harada D; Kozuki T; Nogami N; Bessho A; Hosokawa S; Fukamatsu N; Hotta K; Ohashi K; Kubo T; Yoshioka H; Yokoyama T; Sone N; Kuyama S; Kudo K; Yasugi M; Takigawa N; Oze I; Kiura K
Asia Pac J Clin Oncol; 2019 Aug; 15(4):250-256. PubMed ID: 30938103
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices.
Ess SM; Herrmann C; Frick H; Krapf M; Cerny T; Jochum W; Früh M
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28557060
[TBL] [Abstract][Full Text] [Related]
9. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
10. Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers.
Tan AC; Itchins M; Khasraw M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093103
[TBL] [Abstract][Full Text] [Related]
11. Genetic changes in squamous cell lung cancer: a review.
Heist RS; Sequist LV; Engelman JA
J Thorac Oncol; 2012 May; 7(5):924-33. PubMed ID: 22722794
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic alterations in advanced NSCLC: a molecular super-highway.
Friedlaender A; Perol M; Banna GL; Parikh K; Addeo A
Biomark Res; 2024 Feb; 12(1):24. PubMed ID: 38347643
[TBL] [Abstract][Full Text] [Related]
13. Molecular Targets in Non-Small Cell Lung Cancer.
Griffin R; Ramirez RA
Ochsner J; 2017; 17(4):388-392. PubMed ID: 29230123
[TBL] [Abstract][Full Text] [Related]
14. Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challenge.
Su C; Zhou F; Shen J; Zhao J; O'Brien M
Eur J Cancer; 2017 Sep; 83():266-278. PubMed ID: 28763691
[TBL] [Abstract][Full Text] [Related]
15. Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC.
Bansal P; Osman D; Gan GN; Simon GR; Boumber Y
Front Oncol; 2016; 6():112. PubMed ID: 27200298
[TBL] [Abstract][Full Text] [Related]
16. Concomitant echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation in non-small cell lung cancer patients from eastern India.
Mohapatra PR; Sahoo S; Bhuniya S; Panigrahi MK; Majumdar SKD; Mishra P; Patra S
J Cancer Res Ther; 2020; 16(4):850-854. PubMed ID: 32930129
[TBL] [Abstract][Full Text] [Related]
17. Comparison of clinical and radiological characteristics between anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation in treatment naïve advanced lung adenocarcinoma.
Miao Y; Zhu S; Li H; Zou J; Zhu Q; Lv T; Song Y
J Thorac Dis; 2017 Oct; 9(10):3927-3937. PubMed ID: 29268403
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives.
Genova C; Rossi G; Tagliamento M; Rijavec E; Biello F; Cerbone L; Zullo L; Grossi F
Expert Rev Respir Med; 2020 Apr; 14(4):367-383. PubMed ID: 31917616
[No Abstract] [Full Text] [Related]
19. How and when to use genetic markers for nonsmall cell lung cancer.
Lazarus DR; Ost DE
Curr Opin Pulm Med; 2013 Jul; 19(4):331-9. PubMed ID: 23715289
[TBL] [Abstract][Full Text] [Related]
20. [Targeted therapies for non-small cell lung cancer : state of the art in 2021].
Sibille A; Corhay JL; Vaillant F; Paulus A; Louis R; Duysinx B
Rev Med Liege; 2021 May; 76(5-6):458-463. PubMed ID: 34080380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
